Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Icaritin

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Icaritin?

Icaritin is an investigational drug.

There have been 4 clinical trials for Icaritin. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2013.

The most common disease conditions in clinical trials are Cardiovascular Diseases, Carcinoma, Hepatocellular, and Carcinoma. The leading clinical trial sponsors are Chinese Academy of Medical Sciences, Beijing Shenogen Biomedical Co., Ltd, and NanJing PLA 81 Hospital.

There are three US patents protecting this investigational drug and thirteen international patents.

Recent Clinical Trials for Icaritin
Epimedium Prenylflavonoid (EP) Extract for Osteoporosis and Cardiovascular DiseaseNational University Hospital, SingaporePhase 1
The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma307 Hospital of PLAPhase 2
The Phase II Study of Icaritin in Patients With Advanced Hepatocellular CarcinomaChinese Academy of Medical SciencesPhase 2

See all Icaritin clinical trials

Clinical Trial Summary for Icaritin

Top disease conditions for Icaritin
Top clinical trial sponsors for Icaritin

See all Icaritin clinical trials

US Patents for Icaritin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Icaritin   Start Trial Compositions comprising icariside I and anhydroicaritin and methods for making the same Hauser, Inc. (Boulder, CO)   Start Trial
Icaritin   Start Trial Compounds and methods for treating estrogen receptor-related diseases Shenogen Pharma Group Ltd. (Beijing, CN)   Start Trial
Icaritin   Start Trial Cosmetic composition containing hydrolysates of icariin Amorepacific Corporation (Seoul, KR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Icaritin

Drugname Country Document Number Estimated Expiration Related US Patent
Icaritin Australia 8060401 2020-08-15   Start Trial
Icaritin World Intellectual Property Organization (WIPO) 0213842 2020-08-15   Start Trial
Icaritin China 101528038 2026-10-25   Start Trial
Icaritin European Patent Office 2096916 2026-10-25   Start Trial
Icaritin Japan 2010508284 2026-10-25   Start Trial
Icaritin Japan 5265556 2026-10-25   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.